Register
A new treatment option for patients with HCC |
Journal Updates
eMediNexus Coverage from: 
A new treatment option for patients with HCC
eMediNexus,  11 November 2018
remove_red_eye 891 Views
#Gastroenterology #Internal Medicine #Pathology and Lab Medicine

0 Read Comments                

The FDA has expanded the indications for pembrolizumab (Keytruda) to include advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib (Nexavar)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now